Leerink Starts Coverage on Absci Corporation (ABSI)

Absci Corporation (NASDAQ:ABSI) is one of the 8 Best Genomics Stocks to Buy According to Analysts.

On June 4, Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target. The analyst stated that its “AI-native, clinical-stage story” is anchored by lead asset ABS-20 in Phase 1/2 for androgenetic alopecia, with Phase 2 in endometriosis expected to begin in Q4 2026. The firm flagged an “18-month catalyst path” with multiple readouts, calling it highly binary but among the most attractive in its coverage.

Separately, looking forward, Absci Corporation (NASDAQ:ABSI)’s CEO Sean McClain said that 2026 will be a “data-rich year.” He also stated that ABS-201, a long-acting anti-PRLR antibody, could introduce a new mechanism in alopecia with infrequent dosing. The corporation said it completed dosing across four single ascending dose cohorts. It reported favorable safety and PK trends while starting multiple ascending dose cohorts.

Leerink Starts Coverage on Absci Corporation (ABSI)

The company announced ABS-202, a preclinical anti-PRLR program. It launched an endometriosis advisory board with experts from institutions including Yale, Duke, UCSF, and Mayo Clinic.

Absci Corporation (NASDAQ:ABSI) is a drug and target discovery firm using deep learning AI and synthetic biology to expand the therapeutic potential of proteins.

While we acknowledge the risk and potential of ABSI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABSI and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1